PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts more than Nifty Microcap 250 and 0.8 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shree Ganesh Biotech reported Q1 FY26 (quarter ended 30 June 2025) unaudited results with revenue from operations at Rs 138.36 lacs, down sharply from Rs 355.61 lacs in Q1 FY25 — a roughly 61% year-on-year decline. Despite the revenue fall, the company posted a net profit of Rs 32.70 lacs versus Rs 23.78 lacs in the same quarter last year, helped mainly by a steep drop in cost of materials consumed (Rs 111.97 lacs vs Rs 343.88 lacs). Total income for the quarter stood at Rs 179.89 lacs (including other income of Rs 41.53 lacs) against total expenses of Rs 147.19 lacs. This is a notable swing from the Rs 94.60 lacs loss reported in the preceding quarter (Q4 FY25). The statutory auditor Bipin & Co. issued a clean limited review report with no qualifications or emphasis of matter. EPS stood at Rs 0.01 (not annualised).
Mixed picture for shareholders — the sharp revenue drop is a concern, but the company returned to profitability this quarter thanks to lower input costs. Investors should watch whether the steep revenue decline is a temporary blip or signals weakening demand, and whether margin gains can be sustained.